Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 11, 2025
Champions Oncology (NASDAQ:CSBR), a global preclinical and clinical research services provider specializing in oncology solutions, has scheduled its third quarter fiscal 2025 financial results announcement for Tuesday, March 11, 2025, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Champions Oncology (NASDAQ:CSBR), a global preclinical and clinical research services provider specializing in oncology solutions, has scheduled its third quarter fiscal 2025 financial results announcement for Tuesday, March 11, 2025, after market close.
The company will host a conference call at 4:30 P.M. EDT to discuss the results for the quarter ended January 31, 2025. Investors can join via phone using the access code 403045: Domestic (888-506-0062) or International (973-528-0011). A replay will be available through phone or the company's website investor section within 72 hours using passcode 52158.
Details
News Market Reaction – CSBR
The recorded move for CSBR in the trading session of this news was -0.70%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HACKENSACK, NJ / ACCESS Newswire / March 6, 2025 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the third quarter ended January 31, 2025, on Tuesday, March 11, 2025, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 403045. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode:52158, or by accessing the investors section of the company's website within 72 hours.
About Champions Oncology, Inc.
Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.
Media Inquiries:
Rachel Bunting, MS, MBA
VP, Global Marketing
Marketing@ChampionsOncology.com
Website: https://www.championsoncology.com/
Facebook: https://www.facebook.com/championsoncology/
LinkedIn: https://www.linkedin.com/company/champions-oncology-inc-/
Twitter: @ChampionsOncol1
Instagram: https://www.instagram.com/championsoncology/
SOURCE: Champions Oncology, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.